LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
Year: 2020
Type: conference-abstract
Source: Annals of Oncology
Institutions: National Institutes of Health, National Cancer Institute, Aarhus University Hospital, Harvard University, Massachusetts General Hospital, Vanderbilt University Medical Center, University of Pennsylvania, University of Utah, Hôpital Européen Georges-Pompidou, University of Michigan, University of Pittsburgh, Cambridge University Hospitals NHS Foundation Trust, Merck & Co., Inc., Rahway, NJ, USA (United States), Center for Cancer Research, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3088513121